1. Home
  2. ESNT vs BDTX Comparison

ESNT vs BDTX Comparison

Compare ESNT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESNT
  • BDTX
  • Stock Information
  • Founded
  • ESNT 2008
  • BDTX 2014
  • Country
  • ESNT Bermuda
  • BDTX United States
  • Employees
  • ESNT N/A
  • BDTX N/A
  • Industry
  • ESNT Property-Casualty Insurers
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ESNT Finance
  • BDTX Health Care
  • Exchange
  • ESNT Nasdaq
  • BDTX Nasdaq
  • Market Cap
  • ESNT N/A
  • BDTX 132.5M
  • IPO Year
  • ESNT 2013
  • BDTX 2020
  • Fundamental
  • Price
  • ESNT $61.90
  • BDTX $2.58
  • Analyst Decision
  • ESNT Buy
  • BDTX Strong Buy
  • Analyst Count
  • ESNT 7
  • BDTX 6
  • Target Price
  • ESNT $63.29
  • BDTX $14.83
  • AVG Volume (30 Days)
  • ESNT 693.7K
  • BDTX 1.3M
  • Earning Date
  • ESNT 08-01-2025
  • BDTX 08-05-2025
  • Dividend Yield
  • ESNT 2.00%
  • BDTX N/A
  • EPS Growth
  • ESNT 3.49
  • BDTX N/A
  • EPS
  • ESNT 6.84
  • BDTX 0.09
  • Revenue
  • ESNT $1,262,105,000.00
  • BDTX $70,000,000.00
  • Revenue This Year
  • ESNT $5.40
  • BDTX N/A
  • Revenue Next Year
  • ESNT $3.66
  • BDTX N/A
  • P/E Ratio
  • ESNT $9.04
  • BDTX $29.29
  • Revenue Growth
  • ESNT 9.57
  • BDTX N/A
  • 52 Week Low
  • ESNT $51.61
  • BDTX $1.20
  • 52 Week High
  • ESNT $65.34
  • BDTX $6.75
  • Technical
  • Relative Strength Index (RSI)
  • ESNT 65.63
  • BDTX 60.64
  • Support Level
  • ESNT $60.34
  • BDTX $2.43
  • Resistance Level
  • ESNT $62.02
  • BDTX $2.72
  • Average True Range (ATR)
  • ESNT 1.06
  • BDTX 0.18
  • MACD
  • ESNT 0.19
  • BDTX -0.00
  • Stochastic Oscillator
  • ESNT 97.53
  • BDTX 76.11

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Share on Social Networks: